Lymphoma Clinical Trials

36 trials recruiting in Canada.

Cancer

RecruitingDrugDeviceBehavioralOlder adultsHealthy volunteers

33 trials · showing 30

Comparing Zilovertamab vedotin with Vincristine for diffuse large b-cell lymphoma

Explore this study →

There are 2 groups in this study. Group A receives Zilovertamab vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone, together with one or more of: Rituximab Biosimilar, Prednisolone, Rescue medication and Methylprednisolone. Group B, the comparison group, receives Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone, together with one or more of: Rituximab Biosimilar, Prednisolone and Methylprednisolone.

Sites in Edmonton, Halifax and 3 more cities

  • Phase 3
  • 2 groups
  • Sites in Edmonton, Halifax and 3 more cities
  • Recruiting

Official title: A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

Diffuse Large B-Cell Lymphoma · Merck Sharp & Dohme LLC

Comparing Odronextamab with Rituximab for follicular lymphoma (FL)

Explore this study →

There are 2 groups in this study. Group A receives Odronextamab. Group B, the comparison group, receives Rituximab, together with one or more of: Cyclophosphamide, Doxorubicin, Vincristine, Prednisone/prednisolone and Bendamustine.

Sites in Calgary, Greenfield Park and 3 more cities

  • Phase 3
  • 2 groups
  • Sites in Calgary, Saint John and 3 more cities
  • Recruiting

Official title: A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

Follicular Lymphoma (FL) · Regeneron Pharmaceuticals

Get matched to the best-fit trials

Answer a few questions and we'll find the closest matches for lymphoma.

Comparing Mosunetuzumab with Rituximab for nodular lymphocyte predominant b-cell lymphoma

Explore this study →

There are 2 groups in this study. Group A receives Mosunetuzumab, together with one or more of: Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Fludeoxyglucose F-18 and Positron Emission Tomography. Group B, the comparison group, receives Rituximab and Rituximab and Hyaluronidase Human, together with one or more of: Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Fludeoxyglucose F-18 and Positron Emission Tomography.

One site, in Toronto

  • Phase 2
  • 2 groups
  • One site, in Toronto
  • Recruiting

Official title: Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial

Nodular Lymphocyte Predominant B-Cell Lymphoma · National Cancer Institute (NCI)

Looking for the closest fit?

Get matched →

Ask someone to look with you

Whether or not the results above are what you were looking for, someone at Concord can search with you.

Get notified when a matching trial opens

We'll watch for Lymphoma trials near you.

Lymphoma
Want matched now instead? →
← Back to all conditions

Concord provides information support only. Trial listings come from public registries; eligibility is always determined by the trial site and your care team.